To address the unmet clinical need for high-risk neuroblastoma therapy, we recently identified a therapeutic target, RBM39, a MYC target that regulates pre-mRNA splicing and appears to be essential to neuroblastoma survival30. Here, RBM39 is linked to neuroblastoma.